Cure My Disease

Don't miss your cure!

 Log in / Sign up

Did pandemic precautions lower fungal infections? hospital records hold clues

NCT ID NCT06483815

NEW Knowledge-focused Sponsor: Bekir Sami Uyanık Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers reviewed hospital records from 1,441 patients to compare fungal infection rates during the SARS-CoV-2 pandemic and afterward. They calculated positivity rates for Candida and Aspergillus species and other fungi. The study examines whether infection control measures changed the number of fungal infections over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the analysis identifies which infection control measures worked, hospitals could use that information to protect patients from fungal infections during future outbreaks.
What could go wrong
This is a retrospective review of records from one hospital, so the findings may not apply elsewhere. It cannot prove cause and effect, only describe patterns over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,441 people

The number who actually took part.

Started

Jun 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients diagnosed with pneumonia according to clinical, laboratory and radiological data in the chest diseases, infectious diseases and intensive care unit of Hisar HIntercontinental Hospital

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients over 18 years of age of both genders Exclusion Criteria: * Patients under 18 years of age, * Patients whose demographic, clinical and laboratory data investigated in the study could not be accessed, patients who were diagnosed with fungal infection during hospitalization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aspergillosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aspergillosis candidiasis fungal infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fungal infections

Contacts and locations

Locations

  • Hisar Hospital Intercontinental

    Istanbul, 34768, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.